Judith E. Karp

19.3k total citations · 3 hit papers
275 papers, 14.2k citations indexed

About

Judith E. Karp is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Judith E. Karp has authored 275 papers receiving a total of 14.2k indexed citations (citations by other indexed papers that have themselves been cited), including 154 papers in Hematology, 137 papers in Molecular Biology and 98 papers in Oncology. Recurrent topics in Judith E. Karp's work include Acute Myeloid Leukemia Research (146 papers), Acute Lymphoblastic Leukemia research (49 papers) and Chronic Myeloid Leukemia Treatments (34 papers). Judith E. Karp is often cited by papers focused on Acute Myeloid Leukemia Research (146 papers), Acute Lymphoblastic Leukemia research (49 papers) and Chronic Myeloid Leukemia Treatments (34 papers). Judith E. Karp collaborates with scholars based in United States, Canada and Germany. Judith E. Karp's co-authors include William G. Merz, Philip J. Burke, Rein Saral, Scott H. Kaufmann, John R. Wingard, Michael G. Rinaldi, Jeffrey E. Lancet, B. Douglas Smith, Ivana Gojo and Michael A. McDevitt and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Judith E. Karp

270 papers receiving 13.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole

1991 774 citations Judith E. Karp et al. profile →
Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA

2008 665 citations Judith E. Karp et al. profile →
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome

2002 518 citations Michael A. McDevitt, Judith E. Karp et al. profile →

Peers

Countries citing papers authored by Judith E. Karp

Since Specialization

Citations

This map shows the geographic impact of Judith E. Karp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith E. Karp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith E. Karp more than expected).

Fields of papers citing papers by Judith E. Karp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith E. Karp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith E. Karp. The network helps show where Judith E. Karp may publish in the future.

Co-authorship network of co-authors of Judith E. Karp

This figure shows the co-authorship network connecting the top 25 collaborators of Judith E. Karp. A scholar is included among the top collaborators of Judith E. Karp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith E. Karp. Judith E. Karp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ethics and Clinical Research: Improving Transparency and Informed Consent in Phase I Oncology Trials 2023 ·Journal of Clinical Oncology ·Paul Frankel, Susan Groshen, Jan H. Beumer, (unknown), Edward S. Kim, Judith E. Karp	3
2	Systematic review and meta‐analysis: Prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia 2023 ·Cancer ·(unknown), Xue Geng, Valeriy R. Korostyshevskiy, Judith E. Karp, Catherine Lai	4
3	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia 2021 ·Leukemia Research ·Hetty E. Carraway, Yazeed Sawalha, Ivana Gojo, Min-Jung Lee, Sunmin Lee, Yusuke Tomita, Akira Yuno, (unknown), B. Douglas Smith, Keith W. Pratz, Mark J. Levis, Steven D. Gore, Nilanjan Ghosh, Amy E. DeZern, Amanda L. Blackford, Maria R. Baer, Lia Gore, Richard Piekarz, Jane B. Trepel, Judith E. Karp	10
4	Developing and Implementing an Online Course Framework 2018 ·NSUWorks (Nova Southeastern University) ·(unknown), Judith E. Karp, (unknown), (unknown), (unknown), (unknown), (unknown)	1
5	Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients 2017 ·Clinical Cancer Research ·(unknown), Vijay Ivaturi, Jogarao Gobburu, Jacqueline M. Greer, L. Austin Doyle, James R. Wright, Judith E. Karp, Michelle A. Rudek	9
6	Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies 2017 ·Clinical Cancer Research ·(unknown), Mathangi Gopalakrishnan, Jogarao Gobburu, Jiuping Ji, Jacqueline M. Greer, Richard Piekarz, Judith E. Karp, Keith W. Pratz, Michelle A. Rudek	4
7	Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia 2017 ·Leukemia Research ·Jonathan Webster, Raoul Tibes, (unknown), Amanda L. Blackford, Mark R. Litzow, Mrinal M. Patnaik, Gary L. Rosner, Ivana Gojo, Robert J. Kinders, Lihua Wang, L. Austin Doyle, Catherine J. Huntoon, Larry M. Karnitz, Scott H. Kaufmann, Judith E. Karp, B. Douglas Smith	44
8	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia 2016 ·Clinical Cancer Research ·Keith W. Pratz, Michelle A. Rudek, Ivana Gojo, Mark R. Litzow, Michael A. McDevitt, Jiuping Ji, Larry M. Karnitz, James G. Herman, Robert J. Kinders, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Douglas E. Gladstone, Mark J. Levis, Hua-Ling Tsai, Gary L. Rosner, Alice P. Chen, Scott H. Kaufmann, Judith E. Karp	38
9	Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms 2016 ·Clinical Cancer Research ·Keith W. Pratz, Brian D. Koh, Anand G. Patel, Karen S. Flatten, Weijie Poh, James G. Herman, Robert L. Dilley, Maria I. Harrell, B. Douglas Smith, Judith E. Karp, Elizabeth M. Swisher, Michael A. McDevitt, Scott H. Kaufmann	23
10	Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells 2015 ·Genes & Development ·Haiming Dai, Husheng Ding, X. Wei Meng, Kevin L. Peterson, Paula A. Schneider, Judith E. Karp, Scott H. Kaufmann	40
11	Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro 2012 ·Clinical Cancer Research ·Erin L. Schenk, Brian D. Koh, Karen S. Flatten, Kevin L. Peterson, David Parry, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Larry M. Karnitz, Scott H. Kaufmann	43
12	Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro 2009 ·Cancer Research ·Andrea E. Wahner Hendrickson, Paul Haluska, Paula A. Schneider, David A. Loegering, Kevin Peterson, Ricardo M. Attar, B. Douglas Smith, Charles Erlichman, Marco M. Gottardis, Judith E. Karp, Joan M. Carboni, Scott H. Kaufmann	43
13	Progressive Chromatin Repression and Promoter Methylation of CTNNA1 Associated with Advanced Myeloid Malignancies 2009 ·Cancer Research ·Ying Ye, Michael A. McDevitt, Mingzhou Guo, Wei Zhang, Oliver Galm, Steven D. Gore, Judith E. Karp, Jaroslaw P. Maciejewski, Jeanne Kowalski, Hua-Ling Tsai, Lukasz P. Gondek, Hsing-Chen Tsai, Xiaofei Wang, Craig M. Hooker, B. Douglas Smith, Hetty E. Carraway, James G. Herman	35
14	Acute Myelogenous Leukemia 2007 ·Humana Press eBooks ·Judith E. Karp	2
15	Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of leukemia patients: Implications for occupational surveillance 2007 ·Mutation Research/Genetic Toxicology and Environmental Mutagenesis ·Michael A. McDevitt, Marian Condon, J. Stamberg, Judith E. Karp, Melissa A. McDiarmid	5
16	JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained 2006 ·Leukemia ·David P. Steensma, Rebecca F. McClure, Judith E. Karp, Ayalew Tefferi, Terra L. Lasho, Heather L. Powell, G Dewald, Scott H. Kaufmann	103
17	Pharmacokinetic and Pharmacodynamic Studies of Lestaurtinib (CEP-701) and PKC-412: Cytotoxicity Is Often Dependent on Non-FLT3-Mediated Effects. 2005 ·Blood ·Mark J. Levis, Adam Stine, (unknown), Benjamin D. Smith, Judith E. Karp, Richard M. Stone, Elihu H. Estey, Frank Giles, Hagop M. Kantarjian, Pamela Cohen, Yanfeng Wang, Donald Small	11
18	Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis 2004 ·Cancer Cell ·Wenyong Chen, Timothy K. Cooper, Cynthia A. Zahnow, Michael Overholtzer, Zhao Zhi-quan, Marc Ladanyi, Judith E. Karp, Nalan Gökgöz, Jay S. Wunder, Irene L. Andrulis, Arnold J. Levine, Joseph L. Mankowski, Stephen B. Baylin	130
19	Addition of Etoposide to Initial Therapy of Adult Acute Lymphoblastic Leukemia: A Combined Clinicaland Laboratory Study 1996 ·Leukemia & lymphoma ·Scott H. Kaufmann, Judith E. Karp, Philip J. Burke, Steven D. Gore	11
20	Leukemic Retinopathy 1989 ·Ophthalmology ·David R. Guyer, Andrew Schachat, Susan Vitale, J. Markowitz, Hayden G. Braine, Philip J. Burke, Judith E. Karp, Michael Graham	65

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact